Compare Incyte Corporation (INCY) vs Packaging Corporation of America (PKG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Packaging Corporation of America — how do they compare? Incyte Corporation trades at $118 (market cap $23.11B), while Packaging Corporation of America trades at $229.01 (market cap $20.77B). The key difference: Incyte Corporation and Packaging Corporation of America are close in size by market cap, and Packaging Corporation of America pays a 2.57% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | PKG | |
|---|---|---|
Market Cap | $23.11B | $20.77B |
Sector | Health | Technology |
52-Week High | $118.52 | $246.31 |
52-Week Low | $67.38 | $191.41 |
Enterprise Value | $19.13B | $24.59B |
Dividend Yield | — | 2.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Packaging Corporation of America (PKG) trades at $228.43, down 1.99% today, with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported Q1 2026 EPS of $2.40, beating estimates, but faces margin pressure with net income expected to decline to $741 million in 2026. Recent developments include a 20% dividend increase and upcoming Q2 earnings on July 22, 2026.
PKG presents a balanced outlook with strong institutional support and dividend growth offset by earnings volatility and margin compression. The consensus price target of $256.14 suggests 12% upside potential, but investors should monitor Q2 results and cost management amid inflationary pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Packaging Corporation of America
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →
